The Philippine Food and Drug Administration (FDA) has yet to begin evaluating Sinopharm's application for emergency use authorization (EUA) for its COVID-19 vaccine because required documents are still lacking.
FDA Director-General Eric Domingo stated that only the Phase 1 clinical trial results and a letter of intent have been submitted by South Med Pharma, the local distributor.
Key documents needed for evaluation include Phase 3 clinical trial results and a certificate of good manufacturing practices.
President Rodrigo Duterte has previously said he will wait for the Sinopharm vaccine to receive EUA before getting vaccinated.
The FDA has already granted EUA to Pfizer, AstraZeneca, and Sinovac, with other applications under review.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.




